Latest news with #BrentZettl
Associated Press
9 hours ago
- Business
- Associated Press
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
SASKATOON, Saskatchewan--(BUSINESS WIRE)--Jun 27, 2025-- Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options '). On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement. Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%. Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event. The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors. An early warning report will be filed by the Acquiror under applicable securities laws and will be available on ZYUS's SEDAR+ profile at For more information, please contact the Acquiror at 204-407 Downey Road, Saskatoon, SK S7N 4L8; telephone: (306) 242-2357 View source version on (306) 242-2357 KEYWORD: NORTH AMERICA CANADA INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY SOURCE: ZYUS Life Sciences Corporation Copyright Business Wire 2025. PUB: 06/27/2025 10:53 PM/DISC: 06/27/2025 10:53 PM
National Post
13 hours ago
- Business
- National Post
Brent H. Zettl Provides Update on Holdings of ZYUS Life Sciences Corporation
Article content This press release is issued pursuant to the requirements of National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues Article content SASKATOON, Saskatchewan — Mr. Brent H. Zettl (the ' acquiror '), who serves as the President and CEO and a director of ZYUS Life Sciences Corporation (' ZYUS ') provides updates to his holdings of Common shares (' Common Shares ') in the capital of ZYUS, Common Share purchase warrants of ZYUS (' Warrants ') and options to purchase Common Shares (' Options '). Article content On June 27, 2025, the acquiror participated in a non-brokered private placement of units (' Units ') of ZYUS (the ' Private Placement ') at a price of $0.67 per Unit, with each Unit comprised of one Common Share and one half of one Warrant (each whole Warrant, a ' Private Placement Warrant '). Each Private Placement Warrant entitles the holder to acquire one Common Share at a price of $0.95 for a period of twenty-four months from the date of issuance, subject to certain acceleration provisions. The acquiror acquired, indirectly through 1189115 B.C. LTD. 298,507 Units (comprised of 298,507 Common Shares and 149,253 Warrants) under the Private Placement. Article content Immediately prior to the Private Placement, the acquiror owned, directly and indirectly, and exercised control over 33,730,573 Common Shares and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis (assuming full exercise of all of the convertible securities held by the acquiror). Immediately following the Private Placement and as at the date hereof, the acquiror owns, directly and indirectly, and exercises control over 34,029,080 Common Shares, 149,253 Warrants and 493,108 Options, representing 43.9% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 44.3% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Following the Private Placement, the acquiror's securityholding percentage has decreased by 1.4% on an undiluted basis from the percentage held immediately following the September 2024 Event (as defined below) and by 5.4% on an undiluted basis from the percentage disclosed in the last early warning report filed by the acquiror on June 13, 2023 (the ' 2023 EWR '), and has decreased by 1.6% on a partially diluted basis from the acquiror's securityholding percentage held immediately following the September 2024 Event and by 6.1% on a partially diluted basis from the acquiror's securityholding percentage as at June 13, 2023. The acquiror's securityholding percentage on a partially diluted basis as disclosed in the 2023 EWR (51.68%) was stated in error. The correct securityholding percentage on a partially diluted basis as at June 13, 2023 was 50.5%. Article content Since the completion of the acquisition of ZYUS Life Sciences Inc. by ZYUS in June 2023, the acquiror's securityholding percentage on a partially diluted basis has decreased from 50.5% to his securityholding percentage immediately prior to the Private Placement as a result of certain transactions and events, including the two following transactions which resulted in each case in a decrease in the acquiror's securityholding percentage by 2% or more since the prior event: (i) on July 31, 2024, the acquiror, disposed of 470,000 Common Shares held by 102042227 Saskatchewan Ltd. (' 102 Sask '), an entity controlled by the acquiror to in satisfaction of payments due in the aggregate amount of $432,400 (the ' July 2024 Event '); and (ii) on September 4, 2024,14,088 Warrants with an exercise price of $3.55 per Common Share previously issued to 102 Sask on March 4, 2022 expired unexercised (the ' September 2024 Event '). Immediately prior to the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 34,173,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 48.2% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.8% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 47.6% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 48.1% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the July 2024 Event, the acquiror's securityholding percentage has decreased by 1.7% on an undiluted basis from the acquiror's securityholding percentage as at June 13, 2023 as disclosed in the 2023 EWR and has decreased by 2.3% on a partially diluted basis from the acquior's securityholding percentage as at June 13, 2023 (which was 50.5%). Immediately prior to the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 292,933 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on a partially diluted basis. Immediately following the September 2024 Event, the acquiror owned, directly and indirectly, and exercised control over 33,703,073 Common Shares, 278,845 Warrants and 493,108 Options, representing 45.3% of ZYUS's issued and outstanding Common Shares on an undiluted basis and 45.9% of ZYUS's issued and outstanding Common Shares on partially diluted basis. Following the September 2024 Event, the acquiror's securityholding percentage has decreased by 2.3% on an undiluted basis from the percentage held immediately following the July 2024 Event and has decreased by 2.2% on a partially diluted basis from the percentage held immediately following the July 2024 Event. Article content The Acquiror's transactions were made for investment purposes. The acquiror may, from time to time and at any time, acquire additional securities of ZYUS in the open market or otherwise, and may dispose of any or all of securities of ZYUS in the open market or otherwise at any time and from time to time, and to engage in similar transactions with respect to the securities of ZYUS, the whole depending on market conditions, the business and prospects of ZYUS and other relevant factors. Article content Article content Article content Article content Article content
Yahoo
22-05-2025
- Business
- Yahoo
ZYUS Life Sciences Finalizing Site Initiation for Phase 2A Clinical Trial Advancing Novel Non-Opioid Pain Drug
Paving the way for evidence-based solutions in cancer pain management with its lead drug product, Trichomylin® softgel capsules SASKATOON, Saskatchewan, May 22, 2025--(BUSINESS WIRE)--ZYUS Life Sciences Corporation (the "Company") (TSXV: ZYUS), a Canadian-based life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management, is pleased to announce it is in the process of finalizing site initiation for the initial locations to be used in its Phase 2 UTOPIA (Unique Treatment of Oncology Pain in Advanced Cancer) clinical trial. The Phase 2 UTOPIA clinical trial will consist of Phase 2A ("UTOPIA-1") and Phase 2B ("UTOPIA-2). UTOPIA-1 is a single-arm proof-of-concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Insights gained from UTOPIA-1 will guide the strategy for UTOPIA-2, which will be a randomized, placebo-controlled trial that will further assess safety and efficacy in a larger patient population. Patient enrollment for UTOPIA-1 is expected to begin in early June 2025, across multiple sites in Canada, with interim data from UTOPIA-1 anticipated mid-summer 2025. ZYUS' announcement comes at a time of growing global recognition of the untapped potential of cannabinoids in oncology. A meta-analysis of medial cannabis outcomes and associations with cancer published in Frontiers in Oncology on April 14, 2025, analyzed over 10,000 peer-reviewed studies encompassing 39,767 data points. The findings revealed a "strong consensus" supporting cannabinoids for managing cancer-related symptoms. While researchers highlight the need for further research to assess the full therapeutic potential of cannabinoids, the findings signal a critical shift in the scientific conversation. This emerging body of evidence reinforces the importance of rigorous clinical research, product purity and consistency, and reinforces ZYUS' commitment to advancing evidence-based cannabinoid therapies. "As we finalize site initiation for UTOPIA-1, we are proud to advance clinical development of Trichomylin® softgel capsules," said Brent Zettl, President and CEO of ZYUS. "Our research aims to bridge the gap between conventional treatments like opioids and NSAIDs, and deliver an alternative, evidence-based pharmaceutical option for cancer pain. This trial is a pivotal step in our journey to improve patient outcomes and quality of life." About ZYUS Life Sciences Corporation ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X @ZYUSCorp. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates and introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2, begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025. Any such forward-looking statements may be identified by words such as "expects", "anticipates", "intends", "contemplates", "believes", "projects", "plans", "will" and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, obtain regulatory approval of cannabinoid-based pharmaceutical drug candidates, introduce products that act as alternatives to current pain management therapies such as opioids, use UTOPIA-1 to guide the strategy for UTOPIA-2 begin patient enrollment in June 2025 and obtain interim data respecting UTOPIA-1 by mid-summer 2025 are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. View source version on Contacts For more information, please contact: ZYUS Media Inquiriesmedia@ 1-833-651-7723 ZYUS Investor Relationsinvestors@
National Post
01-05-2025
- Health
- National Post
ZYUS Life Sciences Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent covering Trichomylin® Formulation and Announces Unit Offering
Article content Article content SASKATOON, Saskatchewan — ZYUS Life Sciences Corporation (the ' Company ' and/or ' ZYUS ') (TSX-V: ZYUS), a clinical stage life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates, today announced that the European Patent Office has granted and the opposition period has expired respecting patent No. EP 3962473 entitled 'Formulation For Pain Management'. This patent relates to ZYUS' cannabinoid-based lead drug candidate, Trichomylin ® softgel capsules. The EU patent marks the 9 th issuance of a patent in this patent family, joining other jurisdictions such as the United States, Canada, Australia, Israel, India, Korea, South Africa and Hong Kong. The EU patent has been validated in 22 European countries and carries a term effective until May 1, 2040. Article content 'The grant of this EU patent represents another milestone intended to drive shareholder value through expanded global protection of our novel fixed-dose formulation, Trichomylin ® softgel capsules,' said Brent Zettl, President and CEO of ZYUS. 'We continue to believe in our highly differentiated approach to pain management and look forward to further advancing this non-opioid based pharmaceutical solution to ultimately address areas of significant unmet medical need.' Article content Conservative estimates suggest that chronic pain affects over 1.5 billion people globally, or 20% of the world's population (Goldberg DS, McGee SJ. 'Pain as a global public heath priority' BMC Public Health 2011;11:770-774). With a view to providing a solution to this unmet need, ZYUS is currently advancing the development of Trichomylin ® softgel capsules in a Phase 2a, single-arm proof of concept study to investigate the safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in humans with advanced cancer and moderate to severe cancer-related pain. Interim data from the Phase 2a study is expected late in the second quarter of 2025. For more information about the Phase 2a study, please visit and reference identifier NCT06533657. Article content ZYUS also announced today that it is undertaking a non-brokered private placement of up to 3,030,303 units of the Company (the ' Units ') at a price of $0.66 per Unit for aggregate gross proceeds of up to $2.0 million (the ' Private Placement '). Each Unit is comprised of one common share of the Company (a ' Common Share ') and one-half of one Common Share purchase warrant (each whole Common Share purchase warrant, a ' Warrant '). Each whole Warrant will entitle the holder to acquire one Common Share at a price of $0.94 for a period of twenty-four months from the date of issuance. Article content Proceeds of the Private Placement will be used for general corporate and working capital purposes. No finders fees will be paid in connection with the Private Placement. Article content The Private Placement is expected to close over multiple tranches as the Corporation may determine from time to time, with the first tranche expected to close on or about May 6, 2025. The Private Placement is subject to customary conditions including, but not limited to, receipt of all necessary TSX Venture Exchange (' TSXV '), regulatory and other approvals. Article content All securities issued pursuant to the Private Placement will be subject to a statutory hold period expiring four months plus a day from the date of issuance in accordance with applicable securities legislation in Canada. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the ' U.S. Securities Act '), or any state securities laws, and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities laws or pursuant to available exemptions therefrom. This release does not constitute an offer to sell or a solicitation of an offer to buy of any securities in the United States. Article content ZYUS (TSXV: ZYUS) is a life sciences company focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. Through rigorous scientific exploration and clinical research, ZYUS aims to secure intellectual property protection, safeguarding its innovative therapies and bolstering shareholder value. ZYUS' unwavering commitment extends to obtaining regulatory approval of non-opioid-based pharmaceutical solutions, in pursuit of transformational impact on patients' lives. For additional information, visit or follow us on X (formerly known as Twitter) @ZYUSCorp. Article content This news release contains 'forward-looking information' within the meaning of applicable securities laws relating to the Company's business, the Company's ability to advance clinical research activities, the ability to introduce products that act as alternatives to current pain management therapies such as opioids, the Company's beliefs and expectations regarding potential shareholder value, the Company's expected milestones for the first half of 2025, the timing of initiation or completion of clinical trials and availability of resulting data, the completion of the Private Placement, the aggregate gross proceeds of the Private Placement, the approval of the TSXV and the use of proceeds from the Private Placement. Any such forward-looking statements may be identified by words such as 'expects', 'anticipates', 'intends', 'contemplates', 'believes', 'projects', 'plans', 'will' and similar expressions. Readers are cautioned not to place undue reliance on forward-looking statements. Statements about, among other things, the Company's business, the Company's ability to advance clinical research activities, the ability to introduce products that act as alternatives to current pain management therapies such as opioids, the Company's beliefs and expectations regarding potential shareholder value, the Company's expected milestones for the first half of 2025, the timing of initiation or completion of clinical trials and availability of resulting data, the completion of the Private Placement, the aggregate gross proceeds of the Private Placement, the approval of the TSXV and the use of proceeds from the Private Placement are all forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that the Company will be able to achieve these results. The Company assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances or actual results unless required by applicable law. Article content Article content Article content Article content Article content Contacts Article content For more information, please contact: Article content Article content Article content
